• 1
    Hwu W-J, Lis E, Menell JH, et al. Temozolomide plus thalidomide in patients with brain metastases from melanoma. A phase II study. Cancer. 2005; 103: 25902597.
  • 2
    Koc M, McGregor J, Grecula J, Bauer CJ, Gupta N, Gahbauer RA. Gamma knife radiosurgery for intracranial metastatic melanoma: an analysis of survival and prognostic factors. J Neurooncol. 2005; 71: 307313.
  • 3
    Meier S, Baumert BG, Maier T, et al. Survival and prognostic factors in patients with brain metastases from malignant melanoma. Onkologie. 2004; 27: 145149.
  • 4
    Agarwala SS, Reyderman L, Statkevich P, et al. Pharmacokinetic study of temozolomide penetration into CSF in a patient with dural melanoma. Ann Oncol. 1998; 9( Suppl 4): 138. Abstract 659a.
  • 5
    Stupp R, Ostermann S, Leyvraz S, Csajka C, Buclin T, Decosterd LA. Cerebrospinal fluid levels of temozolomide as a surrogate marker for brain penetration. Proc Am Soc Clin Oncol. 2001; 20: 59a. Abstract.
  • 6
    Yung WKA, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol. 1999; 17: 27622771.
  • 7
    Agarwala SS, Kirkwood JM, Gore M, et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol. 2004; 22: 21012107.
  • 8
    Bafaloukos D, Tsoutsos D, Fountzilas G, et al. The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma. Melanoma Res. 2004; 14: 289294.
  • 9
    Paul MJ, Summers Y, Calvert AH, et al. Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. Melanoma Res. 2002; 12: 175178.
  • 10
    Atkins MB, Gollob JA, Sosman JA, et al. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2 and IFN-alpha 2B in patients with metastatic melanoma. Clin Cancer Res. 2002; 8: 30753081.
  • 11
    Brock CS, Newlands ES, Wedge SR, et al. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res. 1998; 58: 43634367.
  • 12
    Tolcher AW, Gerson SL, Denis L, et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer. 2003; 88: 10041011.
  • 13
    Gander M, Leyvraz S, Decosterd L, et al. Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours. Ann Oncol. 1999; 10: 831838.
  • 14
    Hwu W-J, Krown SE, Panageas KS, et al. Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial. J Clin Oncol. 2002; 20: 26102615.
  • 15
    D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 1994; 91: 40824085.
  • 16
    Hwu W-J, Krown SE, Menell JH, et al. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol. 2003; 21: 33513356.
  • 17
    Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000; 92: 205216.
  • 18
    Bick RL. Cancer-associated thrombosis [editorial]. N Engl J Med. 2003; 349: 109111.
  • 19
    Lee AYY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation. 2003; 107: I17I21.
  • 20
    Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ3rd. Risk factors for deep vein thrombosis and pulmonary embolism. A population-based case-control study. Arch Intern Med. 2000; 160: 809815.
  • 21
    Lee AY. Cancer and thromboembolic disease: pathogenic mechanisms. Cancer Treat Rev. 2002; 28: 137140.
  • 22
    Gerber DE, Grossman SA, Streiff MB. Management of venous thromboembolism in patients with primary and metastatic brain tumors. J Clin Oncol. 2006; 24: 13101318.
  • 23
    Numico G, Garrone O, Dongiovanni V, et al. Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. Cancer. 2005; 103: 994999.
  • 24
    Weijl NI, Rutten MFJ, Zwinderman AH, et al. Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J Clin Oncol. 2000; 18: 21692178.
  • 25
    Czaykowski PM, Moore MJ, Tannock IF. High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy. J Urol. 1998; 160: 20212124.
  • 26
    Levine MN, Gent M, Hirsh J, et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med. 1988; 318: 404407.
  • 27
    Pritchard KI, Paterson AH, Paul NA, Zee B, Fine S, Pater J. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer.National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol. 1996; 14: 27312737.
  • 28
    Clahsen PC, van de Velde CJ, Julien JP, Floiras JL, Mignolet FY. Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: a European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group study. J Clin Oncol. 1994; 12: 12661271.
  • 29
    Rivkin SE, Green S, Metch B, et al. Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. J Clin Oncol. 1994; 12: 20782085.
  • 30
    Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol. 1991; 9: 286294.
  • 31
    Weiss RB, Tormey DC, Holland JF, Weinberg VE. Venous thrombosis during multimodal treatment of primary breast carcinoma. Cancer Treat Rep. 1981; 65: 677679.
  • 32
    Wall JG, Weiss RB, Norton L, et al. Arterial thrombosis associated with adjuvant chemotherapy for breast carcinoma: a Cancer and Leukemia Group B Study. Am J Med. 1989; 87: 501504.
  • 33
    von Tempelhoff GF, Dietrich M, Hommel G, Heilmann L. Blood coagulation during adjuvant epirubicin/cyclophosphamide chemotherapy in patients with primary operable breast cancer. J Clin Oncol. 1996; 14: 25602568.
  • 34
    Goodnough LT, Saito H, Manni A, Jones PK, Pearson OH. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen. A study of 159 patients. Cancer. 1984; 54: 12641268.
  • 35
    Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999; 341: 15651571.
  • 36
    Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood. 2001; 98: 492494.
  • 37
    Zangari M, Anaissie E, Barlogie B, et al. Increased risk of deep vein thrombosis in multiple myeloma patients receiving thalidomide in combination with chemotherapy. Blood. 2001; 98: 16141615.
  • 38
    Zangari M, Siegel E, Barlogie B, et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood. 2002; 100: 11681171.
  • 39
    Urbauer E, Kaufmann H, Nosslinger T, Raderer M, Drach J. Thromboembolic events during treatment with thalidomide. Blood. 2002; 99: 42474248.
  • 40
    Osman K, Comenzo R, Rajkumar SV. Deep venous thrombosis and thalidomide therapy for multiple myeloma [letter]. N Engl J Med. 2001; 344: 19511952.
  • 41
    Desai AA, Vogelzang NJ, Rini BI, et al. A phase II trial of weekly intravenous gemcitabine with prolonged continuous infusion fluorouracil and oral thalidomide in patients with metastatic renal cell carcinoma. Proc Am Soc Clin Oncol. 2001; 20: 2448. Abstract.
  • 42
    Figg W, Arlen P, Gulley J, et al. A randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. Semin Oncol. 2001; 28( Suppl): 62S66S.
  • 43
    Fine HA, Wen PY, Maher EA, et al. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J Clin Oncol. 2003; 21: 22992304.
  • 44
    Zangari M, Saghafifar F, Anaissie E, et al. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis. 2002; 13: 187192.
  • 45
    Zangari M, Barlogie B, Anaissie E, et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol. 2004; 126: 715721.
  • 46
    Schiff D, DeAngelis LM. Therapy of venous thromboembolism in patients with brain metastases. Cancer. 1994; 73: 493498.
  • 47
    Levin JM, Schiff D, Loeffler JS, Fine HA, Black PM, Wen PY. Complications of therapy for venous thromboembolic disease in patients with brain tumors. Neurology. 1993; 43: 11111114.
  • 48
    Knovich MA, Lesser GJ. The management of thromboembolic disease in patients with central nervous system malignancies. Curr Treat Options Oncol. 2004; 5: 511517.